Skip to main content
Top
Published in: Molecular Diagnosis & Therapy 6/2009

01-12-2009 | Review Article

Early Detection of Breast Cancer

New Biomarker Tests on the Horizon?

Authors: Dr Aparna C. Jotwani, Julie R. Gralow

Published in: Molecular Diagnosis & Therapy | Issue 6/2009

Login to get access

Abstract

When cancer is detected early, patients live longer, require less extensive treatment, and in general fare better than patients with more advanced disease. Breast cancer is the most commonly diagnosed cancer among women. Breast cancer screening through mammography has shown significant mortality reduction in clinical trials through the early detection of disease. This article aims to outline novel methods of indirect and direct detection of breast cancer through biomarkers. Proteomics and gene expression profiling methods will likely be important tools in regard to cancer detection in the future. Blood-based biomarker development is the furthest along and, either in the form of proteins or RNA, shows promise to lead to early detection techniques. Unfortunately, procedures aiming to analyze the breast tissue more directly have not had the desired outcomes thus far for the early detection of breast cancer. Appropriate development of these potential early detection and diagnostic tests is necessary prior to their clinical application, with special attention to their specificity to avoid overdiagnosis.
Literature
1.
go back to reference Etzioni R, Urban N, Ramsey M, et al. The case for early detection. Nat Rev Cancer 2003; 3: 243–52PubMedCrossRef Etzioni R, Urban N, Ramsey M, et al. The case for early detection. Nat Rev Cancer 2003; 3: 243–52PubMedCrossRef
3.
go back to reference Levenson VV. Biomarkers for early detection of breast cancer: what, when and where? Biochim Biophys Acta 2007; 1770: 847–56PubMedCrossRef Levenson VV. Biomarkers for early detection of breast cancer: what, when and where? Biochim Biophys Acta 2007; 1770: 847–56PubMedCrossRef
4.
5.
go back to reference Khatcheressian JL, Wolff AC, Smith TJ, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow up and management guidelines in the adjuvant setting. J Clin Oncol 2006; 31: 591–7 Khatcheressian JL, Wolff AC, Smith TJ, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow up and management guidelines in the adjuvant setting. J Clin Oncol 2006; 31: 591–7
6.
go back to reference Winer E, Gralow JR, Diller L, et al. Clinical care advances 2008: major research advances in cancer treatment, prevention and screening: a report from the American Society of Clinical Oncology. J Clin Oncol 2009; 27: 812–26PubMedCrossRef Winer E, Gralow JR, Diller L, et al. Clinical care advances 2008: major research advances in cancer treatment, prevention and screening: a report from the American Society of Clinical Oncology. J Clin Oncol 2009; 27: 812–26PubMedCrossRef
7.
go back to reference Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature 2000; 406: 747–52PubMedCrossRef Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature 2000; 406: 747–52PubMedCrossRef
8.
go back to reference Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2006; (4): CD001877 Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2006; (4): CD001877
9.
go back to reference Humphrey LL, Helfand M, Chan B, et al. Breast cancer screening: a summary of the evidence for the US Preventative Services Task Force. Ann Intern Med 2002; 137: E347–67 Humphrey LL, Helfand M, Chan B, et al. Breast cancer screening: a summary of the evidence for the US Preventative Services Task Force. Ann Intern Med 2002; 137: E347–67
10.
go back to reference Wright T, McGechan A. Breast cancer: new technologies for risk assessment and diagnosis. Mol Diagn 2003; 7: 49–55PubMedCrossRef Wright T, McGechan A. Breast cancer: new technologies for risk assessment and diagnosis. Mol Diagn 2003; 7: 49–55PubMedCrossRef
11.
go back to reference Gralow JR, Ozols RF, Bajorin DF, et al. Clinical care advances 2007: major research advances in cancer treatment, prevention and screening. A report from the American Society of Clinical Oncology. J Clin Oncol 2008; 26: 313–25PubMedCrossRef Gralow JR, Ozols RF, Bajorin DF, et al. Clinical care advances 2007: major research advances in cancer treatment, prevention and screening. A report from the American Society of Clinical Oncology. J Clin Oncol 2008; 26: 313–25PubMedCrossRef
12.
go back to reference Granader EJ, Dwamena B, Carlos RC. MRI and mammography surveillance of women at increased risk for breast cancer: recommendations using an evidence-based approach. Acad Radiol 2008; 15: 1590–5PubMedCrossRef Granader EJ, Dwamena B, Carlos RC. MRI and mammography surveillance of women at increased risk for breast cancer: recommendations using an evidence-based approach. Acad Radiol 2008; 15: 1590–5PubMedCrossRef
15.
go back to reference Somiari RI, Somiari S, Russell S, et al. Proteomics of breast carcinoma. J Chromatogr 2005; 815: 215–25CrossRef Somiari RI, Somiari S, Russell S, et al. Proteomics of breast carcinoma. J Chromatogr 2005; 815: 215–25CrossRef
16.
go back to reference Kelly-Spratt KS, Kasarda AE, Igra M, et al. A mouse model for biomarker discovery. J Proteome Res 2008; 7: 3613–8PubMedCrossRef Kelly-Spratt KS, Kasarda AE, Igra M, et al. A mouse model for biomarker discovery. J Proteome Res 2008; 7: 3613–8PubMedCrossRef
17.
go back to reference Debies MT, Gestl SA, Mathers JL, et al. Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19Arf/p53 pathway lesions but not p16lnk4a loss. J Clin Invest 2008; 118: 51–63PubMedCrossRef Debies MT, Gestl SA, Mathers JL, et al. Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19Arf/p53 pathway lesions but not p16lnk4a loss. J Clin Invest 2008; 118: 51–63PubMedCrossRef
18.
go back to reference Whiteaker JR, Zhang H, Zhao L, et al. Integrated pipeline for mass spectometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J Proteome Res 2007; 6: 3962–75PubMedCrossRef Whiteaker JR, Zhang H, Zhao L, et al. Integrated pipeline for mass spectometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J Proteome Res 2007; 6: 3962–75PubMedCrossRef
19.
go back to reference Pitteri SJ, Faca VM, Kelly-Spratt KS, et al. Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells. J Proteome Res 2008; 7: 1481–9PubMedCrossRef Pitteri SJ, Faca VM, Kelly-Spratt KS, et al. Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells. J Proteome Res 2008; 7: 1481–9PubMedCrossRef
20.
go back to reference Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002; 1: 845–67PubMedCrossRef Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002; 1: 845–67PubMedCrossRef
21.
go back to reference Paulovich AG, Whiteaker JR, Hoofnagle AN, et al. The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Proteomics Clin Appl 2008; 2(10-11): 1386–402PubMedCrossRef Paulovich AG, Whiteaker JR, Hoofnagle AN, et al. The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Proteomics Clin Appl 2008; 2(10-11): 1386–402PubMedCrossRef
22.
go back to reference Ou K, Yu K, Kesuma D, et al. Novel breast cancer biomarkers identified by integrative proteomic and gene expression mapping. J Proteome Res 2008; 7: 1518–28PubMedCrossRef Ou K, Yu K, Kesuma D, et al. Novel breast cancer biomarkers identified by integrative proteomic and gene expression mapping. J Proteome Res 2008; 7: 1518–28PubMedCrossRef
23.
go back to reference Vishwanatha JK, Kumble S. Involvement of annexin II in DNA replication: evidence from cell free extracts of Xenopus eggs. J Cell Sci 1993; 105 (Pt 2): 533–40PubMed Vishwanatha JK, Kumble S. Involvement of annexin II in DNA replication: evidence from cell free extracts of Xenopus eggs. J Cell Sci 1993; 105 (Pt 2): 533–40PubMed
24.
go back to reference Moyano JV, Evans JR, Chen F, et al. Alpha-B crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 2006 Jan; 116(1): 261–70PubMedCrossRef Moyano JV, Evans JR, Chen F, et al. Alpha-B crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest 2006 Jan; 116(1): 261–70PubMedCrossRef
25.
go back to reference Gruvberger-Saal SK, Parsons R. Is the small heat shock protein alphaB crystallin an oncogene? J Clin Invest 2006 Jan; 116(1): 30–2PubMedCrossRef Gruvberger-Saal SK, Parsons R. Is the small heat shock protein alphaB crystallin an oncogene? J Clin Invest 2006 Jan; 116(1): 30–2PubMedCrossRef
26.
go back to reference Feuer EJ, Etzioni R, Cronin KA, et al. The use of modeling to understand the impact of screening on US mortality: examples from mammography to PSA testing. Stat Methods Med Res 2004; 13: 421–42PubMedCrossRef Feuer EJ, Etzioni R, Cronin KA, et al. The use of modeling to understand the impact of screening on US mortality: examples from mammography to PSA testing. Stat Methods Med Res 2004; 13: 421–42PubMedCrossRef
27.
go back to reference DePotter CR, Beghin C, Praet MM, et al. CEA and HMFG in hyperplastic and malignant lesions of the breast. Pathol Res Pract 1988; 183: 271–6CrossRef DePotter CR, Beghin C, Praet MM, et al. CEA and HMFG in hyperplastic and malignant lesions of the breast. Pathol Res Pract 1988; 183: 271–6CrossRef
28.
go back to reference Taylor-Papadimitriou J, Burchell JM, Plunkett T, et al. MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 2002; 7: 209–21PubMedCrossRef Taylor-Papadimitriou J, Burchell JM, Plunkett T, et al. MUC1 and the immunobiology of cancer. J Mammary Gland Biol Neoplasia 2002; 7: 209–21PubMedCrossRef
29.
go back to reference Hounsell EF, Young M, Davies MJ. Glycoprotein changes in tumours: a renaissance in clinical applications. Clin Sci (Lond) 1997; 93(4): 287–93 Hounsell EF, Young M, Davies MJ. Glycoprotein changes in tumours: a renaissance in clinical applications. Clin Sci (Lond) 1997; 93(4): 287–93
30.
go back to reference Reddish MA, Suresh MR, Koganty RR, et al. Analysis of the role of type 1 core O-glycans in the binding of anti-MUC1 antibodies by cytofluorometry and synthetic peptide/glycopeptide binding inhibition studies. Tumour Biol 1998; 19Suppl. 1: 57–66PubMedCrossRef Reddish MA, Suresh MR, Koganty RR, et al. Analysis of the role of type 1 core O-glycans in the binding of anti-MUC1 antibodies by cytofluorometry and synthetic peptide/glycopeptide binding inhibition studies. Tumour Biol 1998; 19Suppl. 1: 57–66PubMedCrossRef
31.
go back to reference Hayes DF. Serum (circulating) tumor markers for breast cancer. Recent Results Cancer Res 1996; 140: 101–13PubMedCrossRef Hayes DF. Serum (circulating) tumor markers for breast cancer. Recent Results Cancer Res 1996; 140: 101–13PubMedCrossRef
32.
go back to reference Ferreira CSM, Papamichael K, Guilbault G, et al. DNA aptamers against the MUC1 tumour marker: design of aptamer-antibody sandwich ELISA for the early diagnosis of epithelial tumors. Anal Bioanal Chem 2008; 390: 1039–50PubMedCrossRef Ferreira CSM, Papamichael K, Guilbault G, et al. DNA aptamers against the MUC1 tumour marker: design of aptamer-antibody sandwich ELISA for the early diagnosis of epithelial tumors. Anal Bioanal Chem 2008; 390: 1039–50PubMedCrossRef
33.
go back to reference Gail MH. Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst 2008; 100: 1037–41PubMedCrossRef Gail MH. Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst 2008; 100: 1037–41PubMedCrossRef
34.
go back to reference Thomas G, Jacobs KB, Kraft P, et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet 2009; 41(5): 579–84PubMedCrossRef Thomas G, Jacobs KB, Kraft P, et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet 2009; 41(5): 579–84PubMedCrossRef
35.
go back to reference Ahmed S, Thomas G, Ghoussaini M, et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet 2009; 41(5): 585–90PubMedCrossRef Ahmed S, Thomas G, Ghoussaini M, et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet 2009; 41(5): 585–90PubMedCrossRef
36.
go back to reference Gaikwad NW, Yang L, Muti P, et al. The molecular etiology of breast cancer: evidence from biomarkers of risk. Int J Cancer 2008; 122: 1949–57PubMedCrossRef Gaikwad NW, Yang L, Muti P, et al. The molecular etiology of breast cancer: evidence from biomarkers of risk. Int J Cancer 2008; 122: 1949–57PubMedCrossRef
37.
go back to reference Disis ML, Pupa SM, Gralow JR, et al. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997; 15: 3363–7PubMed Disis ML, Pupa SM, Gralow JR, et al. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997; 15: 3363–7PubMed
38.
go back to reference Lu H, Goodell V, Disis ML. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res 2008; 7: 1388–94PubMedCrossRef Lu H, Goodell V, Disis ML. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res 2008; 7: 1388–94PubMedCrossRef
39.
go back to reference Anderson KS, Ramachandran N, Wong J, et al. Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res 2008 Apr; 7(4): 1490–9PubMedCrossRef Anderson KS, Ramachandran N, Wong J, et al. Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res 2008 Apr; 7(4): 1490–9PubMedCrossRef
40.
go back to reference Regele S, Hohlberger P, Vogl FD, et al. Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast. Br J Cancer 1999; 81: 702–4PubMedCrossRef Regele S, Hohlberger P, Vogl FD, et al. Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast. Br J Cancer 1999; 81: 702–4PubMedCrossRef
41.
go back to reference Goodell V, Waisman J, Salazar LG, et al. Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol Cancer Ther 2008; 7: 449–54PubMedCrossRef Goodell V, Waisman J, Salazar LG, et al. Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol Cancer Ther 2008; 7: 449–54PubMedCrossRef
42.
go back to reference Raina D, Ahmad R, Joshi MD, et al. Direct targeting of the mucin 1 onco-protein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res 2009 Jun 15; 69(12): 5133–41PubMedCrossRef Raina D, Ahmad R, Joshi MD, et al. Direct targeting of the mucin 1 onco-protein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res 2009 Jun 15; 69(12): 5133–41PubMedCrossRef
43.
go back to reference Leroy X, Buisine MP, Leteurtre E, et al. MUC1 (EMA): a key molecule of carcinogenesis? Ann Pathol 2006 Sep; 26(4): 257–66PubMedCrossRef Leroy X, Buisine MP, Leteurtre E, et al. MUC1 (EMA): a key molecule of carcinogenesis? Ann Pathol 2006 Sep; 26(4): 257–66PubMedCrossRef
44.
go back to reference Hermsen BB, Verheijen RH, Menko FH, et al. Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation. Eur J Cancer 2007; 43: 1556–63PubMedCrossRef Hermsen BB, Verheijen RH, Menko FH, et al. Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation. Eur J Cancer 2007; 43: 1556–63PubMedCrossRef
45.
go back to reference Fabian CJ, Kimler BF, Mayo MS, et al. Breast-tissue sampling for risk assessment and prevention. Endocr Relat Cancer 2005; 12: 185–213PubMedCrossRef Fabian CJ, Kimler BF, Mayo MS, et al. Breast-tissue sampling for risk assessment and prevention. Endocr Relat Cancer 2005; 12: 185–213PubMedCrossRef
46.
go back to reference Gong G, DeVries S, Chew KL, et al. Genetic changes in paired atypical and usual ductal hyperplasia of the breast by comparative genomic hybridization. Clin Cancer Res 2001; 7: 2410–14PubMed Gong G, DeVries S, Chew KL, et al. Genetic changes in paired atypical and usual ductal hyperplasia of the breast by comparative genomic hybridization. Clin Cancer Res 2001; 7: 2410–14PubMed
47.
go back to reference Sartorius OV, Smith HS, Morris P, et al. Cytologic evaluation of breast fluid in the detection of breast disease. J Natl Cancer Inst 1977; 59: 1073–80PubMed Sartorius OV, Smith HS, Morris P, et al. Cytologic evaluation of breast fluid in the detection of breast disease. J Natl Cancer Inst 1977; 59: 1073–80PubMed
48.
go back to reference Wrensch MR, Petrackis NL, King EB, et al. Breast cancer incidence in women with abnormal cytology in nipple aspirates of breast fluid. Am J Epidemiol 1992; 135: 130–41PubMed Wrensch MR, Petrackis NL, King EB, et al. Breast cancer incidence in women with abnormal cytology in nipple aspirates of breast fluid. Am J Epidemiol 1992; 135: 130–41PubMed
49.
go back to reference Wrensch MR, Petrakis NL, Miike R, et al. Breast cancer risk in women with abnormal cytology in nipple aspirates of breast fluid. J Natl Cancer Inst 2001; 93: 1791–8PubMedCrossRef Wrensch MR, Petrakis NL, Miike R, et al. Breast cancer risk in women with abnormal cytology in nipple aspirates of breast fluid. J Natl Cancer Inst 2001; 93: 1791–8PubMedCrossRef
50.
go back to reference Suijkerbuijk KPM, Van Der Wall E, Vooijs M, et al. Molecular analysis of nipple fluid for breast cancer screening. Pathobiology 2008; 75: 146–52CrossRef Suijkerbuijk KPM, Van Der Wall E, Vooijs M, et al. Molecular analysis of nipple fluid for breast cancer screening. Pathobiology 2008; 75: 146–52CrossRef
51.
go back to reference Tice JA, Miike R, Adduci K, et al. Nipple aspirate fluid cytology and the Gail model for breast cancer risk assessment in a screening population. Cancer Epidemiol Biomarkers Prev 2005; 14: 324–8PubMedCrossRef Tice JA, Miike R, Adduci K, et al. Nipple aspirate fluid cytology and the Gail model for breast cancer risk assessment in a screening population. Cancer Epidemiol Biomarkers Prev 2005; 14: 324–8PubMedCrossRef
52.
go back to reference Baltzell KA, Moghadassi M, Rice T, et al. Epithelial cells in nipple aspirate fluid and subsequent breast cancer risk: a historic prospective study. BMC Cancer 2008; 8: 75–81PubMedCrossRef Baltzell KA, Moghadassi M, Rice T, et al. Epithelial cells in nipple aspirate fluid and subsequent breast cancer risk: a historic prospective study. BMC Cancer 2008; 8: 75–81PubMedCrossRef
53.
go back to reference Buehring G, Letscher A, McGirr K, et al. Presence of epithelial cells in nipple aspirate fluid is associated with subsequent breast cancer: a 25-year prospective study. Breast Cancer Res Treat 2006; 98: 63–70PubMedCrossRef Buehring G, Letscher A, McGirr K, et al. Presence of epithelial cells in nipple aspirate fluid is associated with subsequent breast cancer: a 25-year prospective study. Breast Cancer Res Treat 2006; 98: 63–70PubMedCrossRef
54.
go back to reference Tondre J, Nejad M, Casano A, et al. Technical enhancements to breast ductal lavage. Ann Surg Oncol 2008; 15: 2734–8PubMedCrossRef Tondre J, Nejad M, Casano A, et al. Technical enhancements to breast ductal lavage. Ann Surg Oncol 2008; 15: 2734–8PubMedCrossRef
55.
go back to reference Visvanathan K, Santor D, Ali SZ, et al. The reliability of nipple aspirate and ductal lavage in women at increased risk for breast cancer: a potential tool for breast cancer risk assessment and biomarker evaluation. Cancer Epidemiol Biomarkers Prev 2007; 16: 950–5PubMedCrossRef Visvanathan K, Santor D, Ali SZ, et al. The reliability of nipple aspirate and ductal lavage in women at increased risk for breast cancer: a potential tool for breast cancer risk assessment and biomarker evaluation. Cancer Epidemiol Biomarkers Prev 2007; 16: 950–5PubMedCrossRef
56.
go back to reference Lithgow D, Nyamathi A, Elashoff D, et al. C-reactive fluid in nipple aspirate fluid associated with Gail model factors. Biol Res Nurs 2007; 9: 108–16PubMedCrossRef Lithgow D, Nyamathi A, Elashoff D, et al. C-reactive fluid in nipple aspirate fluid associated with Gail model factors. Biol Res Nurs 2007; 9: 108–16PubMedCrossRef
57.
go back to reference Arun B, Valero V, Logan C, et al. Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials. Clin Cancer Res 2007; 13: 4943–8PubMedCrossRef Arun B, Valero V, Logan C, et al. Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials. Clin Cancer Res 2007; 13: 4943–8PubMedCrossRef
58.
go back to reference Cazzaniga M, Gheit T, Casadio C, et al. Analysis of the presence of cutaneous and mucosal papillomavirus types in ductal lavage fluid, milk and colostrum to evaluate its role in breast carcinogenesis. Breast Cancer Res Treat 2009; 114: 599–605PubMedCrossRef Cazzaniga M, Gheit T, Casadio C, et al. Analysis of the presence of cutaneous and mucosal papillomavirus types in ductal lavage fluid, milk and colostrum to evaluate its role in breast carcinogenesis. Breast Cancer Res Treat 2009; 114: 599–605PubMedCrossRef
59.
go back to reference Amarante MK, Watanabe MA, et al. The possible involvement of virus in breast cancer. J Cancer Res Clin Oncol 2009; 135(3): 329–37PubMedCrossRef Amarante MK, Watanabe MA, et al. The possible involvement of virus in breast cancer. J Cancer Res Clin Oncol 2009; 135(3): 329–37PubMedCrossRef
60.
go back to reference Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105: 10513–8PubMedCrossRef Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105: 10513–8PubMedCrossRef
Metadata
Title
Early Detection of Breast Cancer
New Biomarker Tests on the Horizon?
Authors
Dr Aparna C. Jotwani
Julie R. Gralow
Publication date
01-12-2009
Publisher
Springer International Publishing
Published in
Molecular Diagnosis & Therapy / Issue 6/2009
Print ISSN: 1177-1062
Electronic ISSN: 1179-2000
DOI
https://doi.org/10.1007/BF03256340

Other articles of this Issue 6/2009

Molecular Diagnosis & Therapy 6/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.